Archive

  • An Update On Proton Pump Inhibitors As A Treatment Of Peptic Ulcers And Gastroesophageal Reflux Disease Gerd
  • Kiet School Of Pharmacy, Kiet Groups Of Institutions, Delhi-NCR,201206

Abstract

Proton pump inhibitors (PPIs) are a class of drugs commonly used to treat a range of conditions that involve excess stomach acid production. In recent years, there have been several updates regarding the use of PPIs in these conditions. In this review article, we provide an overview of the mechanism of action of PPIs, their clinical efficacy and safety, and their use in the treatment of GERD. We discuss evidence supporting the use of PPIs in the management of GERD, as well as their potential side effects and risks. We also explore alternative treatment options for GERD and highlight the importance of lifestyle modifications in managing this condition. Overall, this review article aims to provide a comprehensive update on the use of PPIs in the treatment of GERD, offering insights and guidance for healthcare providers in the management of this common condition. We talk about the possible risk of long-term PPI usage, including an elevated risk of infections and bone fractures, and the ongoing debate about the appropriate duration of PPI therapy for GERD. Overall, PPIs are an important treatment option for patients with GERD, offering significant symptom relief and promoting the healing of oesophageal erosions. However, their long-term use should be carefully considered, and alternative treatment options should be explored when appropriate. Close monitoring and regular follow-up are important for patients taking PPIs to ensure optimal outcomes and minimize potential risks.

Keywords

Gastroesophageal Reflux Disease, peptic ulcers, Proton pump inhibitors, Treatment

Reference

  1. Roche VF. The chemically elegant proton pump inhibitors. Am J Pharm Educ 2006;70. https://doi.org/10.5688/AJ7005101.
  2. Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005;54:710–7. https://doi.org/10.1136/GUT.2004.051821.
  3. Locke GR, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997;112:1448–56. https://doi.org/10.1016/S0016-5085(97)70025-8.
  4. Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis 1976;21:953–6. https://doi.org/10.1007/BF01071906.
  5. Sandler RS, Everhart JE, Donowitz M, Adams E, Cronin K, Goodman C, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002;122:1500–11. https://doi.org/10.1053/gast.2002.32978.
  6. Dean BB, Gano AD, Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clinical Gastroenterology and Hepatology 2004;2:656–64. https://doi.org/10.1016/S1542-3565(04)00288-5.
  7. Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil 2013;19:25–35. https://doi.org/10.5056/JNM.2013.19.1.25.
  8. Leontiadis GI, McIntyre L, Sharma VK, Howden CW. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev 2004. https://doi.org/10.1002/14651858.CD002094.PUB2.
  9. Leontiadis GI, Sharma VK, Howden CW. Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding. BMJ 2005;330:568–70. https://doi.org/10.1136/BMJ.38356.641134.8F.
  10. Vergara M, Catalán M, Gisbert JP, Calvet X. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005;21:1411–8. https://doi.org/10.1111/J.1365-2036.2005.02444.X.
  11. Heidelbaugh JJ, Kim AH, Walker PC. Overutilization of proton-pump inhibitors: what the clinician needs to know. Therap Adv Gastroenterol 2012;5:219–32. https://doi.org/10.1177/1756283X12437358.
  12. Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc (Wash) 2000;40. https://doi.org/10.1016/S1086-5802(16)31036-1.
  13. Olbe L, Carlsson E, Lindberg P. A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat Rev Drug Discov 2003;2:132–9. https://doi.org/10.1038/NRD1010.
  14. Schunack W. What are the differences between the H2-receptor antagonists? Aliment Pharmacol Ther 1987;1 Suppl 1. https://doi.org/10.1111/J.1365-2036.1987.TB00658.X.
  15. Welage LS. Pharmacologic properties of proton pump inhibitors. Pharmacotherapy 2003;23. https://doi.org/10.1592/PHCO.23.13.74S.31929.
  16. Herszényi L, Bakucz T, Barabás L, Tulassay Z. Pharmacological Approach to Gastric Acid Suppression: Past, Present, and Future. Dig Dis 2020;38:104–11. https://doi.org/10.1159/000505204.
  17. Huang JQ, Hunt RH. Pharmacological and pharmacodynamic essentials of H2-receptor antagonists and proton pump inhibitors for the practising physician. Best Pract Res Clin Gastroenterol 2001;15:355–70. https://doi.org/10.1053/bega.2001.0184.
  18. Shin JM, Munson K, Vagin O, Sachs G. The gastric HK-ATPase: structure, function, and inhibition. Pflugers Arch 2009;457:609–22. https://doi.org/10.1007/S00424-008-0495-4.
  19. Sachs G, Shin JM, Vagin O, Lambrecht N, Yakubov I, Munson K. The gastric H,K ATPase as a drug target: past, present, and future. J Clin Gastroenterol 2007;41 Suppl 2. https://doi.org/10.1097/MCG.0B013E31803233B7.
  20. Scarpignato C, Hunt RH. The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease. Curr Opin Gastroenterol 2019;35:344–55. https://doi.org/10.1097/MOG.0000000000000543.
  21. Oshima T, Miwa H. Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases. J Neurogastroenterol Motil 2018;24:334–44. https://doi.org/10.5056/JNM18029.
  22. Herranz R. Cholecystokinin antagonists: pharmacological and therapeutic potential. Med Res Rev 2003;23:559–605. https://doi.org/10.1002/MED.10042.
  23. Maton PN, Jensen RT, Gardner JD. Cholecystokinin antagonists. Horm Metab Res 1986;18:2–9. https://doi.org/10.1055/S-2007-1012212.
  24. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet] - PubMed n.d. https://pubmed.ncbi.nlm.nih.gov/31643176/ (accessed April 29, 2023).
  25. Daly MJ, Price BJ. Ranitidine and other H2-receptor antagonists: recent developments. Prog Med Chem 1983;20:337–68. https://doi.org/10.1016/S0079-6468(08)70221-2.
  26. Nizatidine, an H2-blocker. Its metabolism and disposition in man - PubMed n.d. https://pubmed.ncbi.nlm.nih.gov/2870891/ (accessed April 29, 2023).
  27. Wiesner A, Zwoli?ska-Wcis?o M, Pa?ko P. Effect of Food and Dosing Regimen on Safety and Efficacy of Proton Pump Inhibitors Therapy-A Literature Review. Int J Environ Res Public Health 2021;18. https://doi.org/10.3390/IJERPH18073527.
  28. Vakil N, Van Zanten S V., Kahrilas P, Dent J, Jones R, Bianchi LK, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101. https://doi.org/10.1111/J.1572-0241.2006.00630.X.
  29. Kahrilas PJ. Diagnosis of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003;98. https://doi.org/10.1016/S0002-9270(03)00011-X.
  30. Freston JW, Jackson RL, Huang B, Ballard ED. Lansoprazole for maintenance of remission of erosive oesophagitis. Drugs 2002;62:1173–84. https://doi.org/10.2165/00003495-200262080-00004.
  31. Nocon M, Labenz J, Jaspersen D, Meyer-Sabellek W, Stolte M, Lind T, et al. Long-term treatment of patients with gastro-oesophageal reflux disease in routine care - results from the ProGERD study. Aliment Pharmacol Ther 2007;25:715–22. https://doi.org/10.1111/J.1365-2036.2007.03249.X.
  32. Scholten T. Long-term management of gastroesophageal reflux disease with pantoprazole. Ther Clin Risk Manag 2007;3:231–43. https://doi.org/10.2147/TCRM.2007.3.2.231.
  33. Hollenz M, Stolte M, Labenz J. [Prevalence of gastro-oesophageal reflux disease in general practice]. Dtsch Med Wochenschr 2002;127:1007–12. https://doi.org/10.1055/S-2002-28325.
  34. Revicki DA, Wood M, Maton PN, Sorensen S. The impact of gastroesophageal reflux disease on health-related quality of life. American Journal of Medicine 1998;104:252–8. https://doi.org/10.1016/S0002-9343(97)00354-9.
  35. Enck P, Dubois D, Marquis P. Quality of life in patients with upper gastrointestinal symptoms: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol Suppl 1999;231:48–54. https://doi.org/10.1080/003655299750025264.
  36. Dimenäs E, Glise H, Hallerbäck B, Hernqvist H, Svedlund J, Wiklund I. Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens? Scand J Gastroenterol 1993;28:681–7. https://doi.org/10.3109/00365529309098272.
  37. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005;100:190–200. https://doi.org/10.1111/J.1572-0241.2005.41217.X.
  38. Fischer J, Robin Ganellin C. Analogue-based Drug Discovery. Analogue-Based Drug Discovery 2006:1–575. https://doi.org/10.1002/3527608001.
  39. Poole P. Pantoprazole. Am J Health Syst Pharm 2001;58:999–1008. https://doi.org/10.1093/AJHP/58.11.999.
  40. Cheer SM, Prakash A, Faulds D, Lamb HM. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs 2003;63:101–32. https://doi.org/10.2165/00003495-200363010-00006.
  41. Hershcovici T, Fass R. Pharmacological management of GERD: Where does it stand now? Trends Pharmacol Sci 2011;32:258–64. https://doi.org/10.1016/j.tips.2011.02.007.
  42. Sherman PM, Hassall E, Fagundes-Neto U, Gold BD, Kato S, Koletzko S, et al. A global, evidence-based consensus on the definition of gastroesophageal reflux disease in the pediatric population. Am J Gastroenterol 2009;104:1278–95. https://doi.org/10.1038/AJG.2009.129.
  43. Tolia V, Vandenplas Y. Systematic review: the extra-oesophageal symptoms of gastro-oesophageal reflux disease in children. Aliment Pharmacol Ther 2009;29:258–72. https://doi.org/10.1111/J.1365-2036.2008.03879.X.
  44. Vandenplas Y, Rudolph CD, Di Lorenzo C, Hassall E, Liptak G, Mazur L, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr 2009;49:498–547. https://doi.org/10.1097/MPG.0B013E3181B7F563.
  45. Fox RK, Muniraj T. Pharmacologic Therapies in Gastrointestinal Diseases. Med Clin North Am 2016;100:827–50. https://doi.org/10.1016/J.MCNA.2016.03.009.
  46. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer - PubMed n.d. https://pubmed.ncbi.nlm.nih.gov/8590162/ (accessed April 29, 2023).
  47. Chan WH, Khin LW, Chung YFA, Goh YC, Ong HS, Wong WK. Randomized controlled trial of standard versus high-dose intravenous omeprazole after endoscopic therapy in high-risk patients with acute peptic ulcer bleeding. Br J Surg 2011;98:640–4. https://doi.org/10.1002/BJS.7420.
  48. Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2013;2013. https://doi.org/10.1002/14651858.CD002095.PUB5.
  49. Prevention of recurrence of oesophageal stricture, a comparison of lansoprazole and high-dose ranitidine - PubMed n.d. https://pubmed.ncbi.nlm.nih.gov/8804870/ (accessed April 29, 2023).
  50. Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci 2011;56:931–50. https://doi.org/10.1007/S10620-010-1560-3.
  51. Caro JJ, Salas M, Ward A. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. Clin Ther 2001;23:998–1017. https://doi.org/10.1016/S0149-2918(01)80087-4.
  52. Gisbert JP, González L, Calvet X, Roqué M, Gabriel R, Pajares JM. Proton pump inhibitors versus H2-antagonists: a meta-analysis of their efficacy in treating bleeding peptic ulcer. Aliment Pharmacol Ther 2001;15:917–26. https://doi.org/10.1046/J.1365-2036.2001.01012.X.
  53. Farup PG, Juul-Hansen PH, Rydning A. Does short-term treatment with proton pump inhibitors cause rebound aggravation of symptoms? J Clin Gastroenterol 2001;33:206–9. https://doi.org/10.1097/00004836-200109000-00007.
  54. Gillen D, Wirz AA, McColl KEL. Helicobacter pylori Eradication Releases Prolonged Increased Acid Secretion Following Omeprazole Treatment. Gastroenterology 2004;126:980–8. https://doi.org/10.1053/j.gastro.2004.01.004.
  55. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis. Gastroenterology 1997;112:1798–810. https://doi.org/10.1053/gast.1997.v112.pm9178669.
  56. Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: An update. Drug Saf 2014;37:201–11. https://doi.org/10.1007/S40264-014-0144-0/TABLES/1.
  57. Cheer SM, Prakash A, Faulds D, Lamb HM. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs 2003;63:101–32. https://doi.org/10.2165/00003495-200363010-00006.
  58. Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 2008;64:935–51. https://doi.org/10.1007/S00228-008-0538-Y.
  59. Strand DS, Kim D, Peura DA. 25 Years of Proton Pump Inhibitors: A Comprehensive Review. Gut Liver 2017;11:27–37. https://doi.org/10.5009/GNL15502.
  60. Sachs G, Shin JM, Vagin O, Lambrecht N, Yakubov I, Munson K. The gastric H,K ATPase as a drug target: past, present, and future. J Clin Gastroenterol 2007;41 Suppl 2. https://doi.org/10.1097/MCG.0B013E31803233B7.
  61. Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep 2008;10:528–34. https://doi.org/10.1007/S11894-008-0098-4.
  62. Welage LS. Pharmacologic properties of proton pump inhibitors. Pharmacotherapy 2003;23. https://doi.org/10.1592/PHCO.23.13.74S.31929.
  63. Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil 2013;19:25–35. https://doi.org/10.5056/JNM.2013.19.1.25.
  64. Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs 2003;63:2739–54. https://doi.org/10.2165/00003495-200363240-00004.
  65. Olbe L, Carlsson E, Lindberg P. A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat Rev Drug Discov 2003;2:132–9. https://doi.org/10.1038/NRD1010.
  66. Stedman CAM, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000;14:963–78. https://doi.org/10.1046/J.1365-2036.2000.00788.X.
  67. Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther 2006;23 Suppl 2:2–8. https://doi.org/10.1111/J.1365-2036.2006.02943.X.
  68. CMS. Proton Pump Inhibitors: U.S. Food and Drug Administration-Approved Indications and Dosages for Use in Adults n.d.
  69. Black JW, Duncan WAM, Durant CJ, Ganellin CR, Parsons EM. Definition and antagonism of histamine H 2 -receptors. Nature 1972;236:385–90. https://doi.org/10.1038/236385A0.
  70. Milton-Thompson GJ, Jenkins DJA, Williams JG, Misiewicz JJ. Inhibition of nocturnal acid secretion in duodenal ulcer by one oral dose of metiamide. Lancet 1974;1:693–4. https://doi.org/10.1016/S0140-6736(74)92901-8.
  71. Shin JM, Sachs G. Pharmacology of Proton Pump Inhibitors. Curr Gastroenterol Rep 2008;10:528. https://doi.org/10.1007/S11894-008-0098-4.
  72. Savarino V, Di Mario F, Scarpignato C. Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety. Pharmacol Res 2009;59:135–53. https://doi.org/10.1016/J.PHRS.2008.09.016.
  73. Asian Journal of Research in Pharmaceutical Sciences n.d. https://ajpsonline.com/HTMLPaper.aspx?Journal=Asian Journal of Research in Pharmaceutical Sciences;PID=2013-3-2-9 (accessed May 1, 2023).
  74. Talley NJ, Ford AC. Functional Dyspepsia. N Engl J Med 2015;373:1853–63. https://doi.org/10.1056/NEJMRA1501505.
  75. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296:2947–53. https://doi.org/10.1001/JAMA.296.24.2947.
  76. Guyatt G, Haynes B, Jeaschke R, Cook D, Greenhalgh T, Meade M, et al. Users’ Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice. Journal of the Medical Library Association 2002;90:483.
  77. Tryba M, Cook DJ. Gastric alkalinization, pneumonia, and systemic infections: the controversy. Scand J Gastroenterol Suppl 1995;210:53–9. https://doi.org/10.3109/00365529509090272.
  78. Haastrup PF, Thompson W, Søndergaard J, Jarbøl DE. Side Effects of Long-Term Proton Pump Inhibitor Use: A Review. Basic Clin Pharmacol Toxicol 2018;123:114–21. https://doi.org/10.1111/bcpt.13023.
  79. Scarpignato C, Group for the S-A-F, Gatta L, Zullo A, Blandizzi C, on behalf of the Italian Society of Pharmacology the IA of HG and the IF of GP. Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression. BMC Med 2016;14.
  80. Ali T, Roberts DN, Tierney WM. Long-term Safety Concerns with Proton Pump Inhibitors. American Journal of Medicine 2009;122:896–903. https://doi.org/10.1016/j.amjmed.2009.04.014.
  81. Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ 2011;183:310–9. https://doi.org/10.1503/CMAJ.092129.
  82. Ogielska M, Lanotte P, Le Brun C, Valentin AS, Garot D, Tellier AC, et al. Emergence of community-acquired Clostridium difficile infection: the experience of a French hospital and review of the literature. Int J Infect Dis 2015;37:36–41. https://doi.org/10.1016/J.IJID.2015.06.007.
  83. Andrès E, Loukili NH, Noel E, Kaltenbach G, Ben Abdelgheni M, Perrin AE, et al. Vitamin B12 (cobalamin) deficiency in elderly patients. CMAJ 2004;171:251–9. https://doi.org/10.1503/CMAJ.1031155.
  84. Howden CW. Vitamin B12 levels during prolonged treatment with proton pump inhibitors. J Clin Gastroenterol 2000;30:29–33. https://doi.org/10.1097/00004836-200001000-00006.
  85. Praga M, Sevillano A, Aunon P, Gonzalez E. Changes in the aetiology, clinical presentation and management of acute interstitial nephritis, an increasingly common cause of acute kidney injury. Nephrol Dial Transplant 2015;30:1472–9. https://doi.org/10.1093/NDT/GFU326.
  86. Klassen S, Krepinsky JC, Prebtani APH. Pantoprazole-induced acute interstitial nephritis. CMAJ 2013;185:56–9. https://doi.org/10.1503/CMAJ.120954.
  87. Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z. Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD. J Am Soc Nephrol 2016;27:3153–63. https://doi.org/10.1681/ASN.2015121377.
  88. GW B-L, GR D, DJ B, SG M, C SA, JS F. An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium. J Clin Invest 1984;73:640–7. https://doi.org/10.1172/JCI111254.
  89. Farina C, Gagliardi S. Selective inhibition of osteoclast vacuolar H(+)-ATPase. Curr Pharm Des 2002;8:2033–48. https://doi.org/10.2174/1381612023393369.
  90. Reimer C, Søndergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 2009;137. https://doi.org/10.1053/J.GASTRO.2009.03.058.
  91. Juul-Hansen P, Rydning A. Clinical and pathophysiological consequences of on-demand treatment with PPI in endoscopy-negative reflux disease. Is rebound hypersecretion of acid a problem? Scand J Gastroenterol 2011;46:398–405. https://doi.org/10.3109/00365521.2010.537684.
  92. Kim YJ, Lee JS, Hong KS, Chung JW, Kim JH, Hahm KB. Novel application of proton pump inhibitor for the prevention of colitis-induced colorectal carcinogenesis beyond acid suppression. Cancer Prev Res (Phila) 2010;3:963–74. https://doi.org/10.1158/1940-6207.CAPR-10-0033.
  93. Mégraud F, Lamouliatte H. Helicobacter pylori and duodenal ulcer. Evidence suggesting causation. Dig Dis Sci 1992;37:769–72. https://doi.org/10.1007/BF01296437.
  94. Graham DY, Lew GM, Klein PD, Evans DG, Evans DJ, Saeed ZA, et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med 1992;116:705–8. https://doi.org/10.7326/0003-4819-116-9-705.
  95. Zagari RM, Romano M, Ojetti V, Stockbrugger R, Gullini S, Annibale B, et al. Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015. Dig Liver Dis 2015;47:903–12. https://doi.org/10.1016/J.DLD.2015.06.010.
  96. Nyssen OP, McNicholl AG, Megraud F, Savarino V, Oderda G, Fallone CA, et al. Sequential versus standard triple first-line therapy for Helicobacter pylori eradication. Cochrane Database Syst Rev 2016;2016. https://doi.org/10.1002/14651858.CD009034.PUB2.
  97. Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev 2006:CD003840. https://doi.org/10.1002/14651858.CD003840.pub4.
  98. COLIN?JONES DG. The role and limitations of H2-receptor antagonists in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995;9 Suppl 1:9–14. https://doi.org/10.1111/J.1365-2036.1995.TB00778.X.
  99. Wilder-Smith CH, Merki HS. Tolerance during dosing with H2-receptor antagonists. An overview. Scand J Gastroenterol Suppl 1992;193:14–9. https://doi.org/10.3109/00365529209096000.
  100. Lachman L, Howden CW. Twenty-four-hour intragastric pH: tolerance within 5 days of continuous ranitidine administration. Am J Gastroenterol 2000;95:57–61. https://doi.org/10.1111/J.1572-0241.2000.01701.X.
  101. Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998;93:763–7. https://doi.org/10.1111/J.1572-0241.1998.221_A.X.
  102. Xue S, Katz PO, Banerjee P, Tutuian R, Castell DO. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther 2001;15:1351–6. https://doi.org/10.1046/J.1365-2036.2001.01050.X.
  103. Savarino V, Di Mario F, Scarpignato C. Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety. Pharmacol Res 2009;59:135–53. https://doi.org/10.1016/J.PHRS.2008.09.016.
  104. Marchetti F, Gerarduzzi T, Ventura A. Proton pump inhibitors in children: a review. Dig Liver Dis 2003;35:738–46. https://doi.org/10.1016/S1590-8658(03)00420-1.
  105. Ali T, Roberts DN, Tierney WM. Long-term safety concerns with proton pump inhibitors. Am J Med 2009;122:896–903. https://doi.org/10.1016/J.AMJMED.2009.04.014.
  106. George CJ, Korc B, Ross JS. Appropriate proton pump inhibitor use among older adults: a retrospective chart review. Am J Geriatr Pharmacother 2008;6:249–54. https://doi.org/10.1016/J.AMJOPHARM.2008.12.001.
  107. Ali RAR, Egan LJ. Gastroesophageal reflux disease in pregnancy. Best Pract Res Clin Gastroenterol 2007;21:793–806. https://doi.org/10.1016/J.BPG.2007.05.006

image
Vikash Kumar
Corresponding author

Kiet School Of Pharmacy, Kiet Groups Of Institutions, Delhi-NCR,201206

image
Sanjeev Kumar Chauhan
Co-author

Kiet School Of Pharmacy, Kiet Groups Of Institutions, Delhi-NCR,201206

Vikash Kumar*, Sanjeev Kumar Chauhan, An Update On Proton-Pump Inhibitors As A Treatment Of Peptic Ulcers And Gastroesophageal Reflux Disease (Gerd), Int. J. in Pharm. Sci., 2023, Vol 1, Issue 11, 1-17. https://doi.org/10.5281/zenodo.10060470

More related articles
A Comparative Evaluation Of Central Nervous System...
Sireesha Kalva, Ramya Yenni, Arravolu Madhu, ...
Review On : Orphan Diseases And Treatment...
Shweta P. Manapure, Jayshree R. Khade, Vaibhav P. Uplanchiwar, Vi...
A Review On Sustained Release Oral Drug Delivery ...
Sonawane Sudha , Sonali S. Sonawane , Vikas B. Wamane, ...
Formulation and Evaluation of Sustained Release Tablet of an AntiDiabetic Drug V...
Mayur Gokul Jayswal, Vasudev Sharma, Adnan Siddiqui, Raza Khan, Shaikh Aaqueeb Ahmed, Afsar Shaikh, ...
A Review On Analytical Methods For Estimation Of Naloxone Hcl And Buprenorphine ...
Kalpana C. Sable, Vinayak M. Gaware, Mayur T. Gaikar, Vivekanand A. Kashid, Jaya V. Mehetre, ...
Related Articles
Formulation And Evaluation Of Herbal Anti Dandruff Shampoo...
Rashmi C., Sariful Islam, Ashraful Anowar, Asraful Ambiya, Mohammad Rafid, Shiyas M. P., ...
Enhancing Patient Care With AI Chatbots And Virtual Assistants...
Asma Shaikh , Haritha CK, Arina Mullick, Varun Gadia, ...
A Review On Analytical Methods For Estimation Of Naloxone Hcl And Buprenorphine ...
Kalpana C. Sable, Vinayak M. Gaware, Mayur T. Gaikar, Vivekanand A. Kashid, Jaya V. Mehetre, ...
A Comparative Analysis Of In-Process Quality Control Parameters Of Montelukast S...
Trupti Yogesh Pawar, Tanishka Anil Pawar, Rahul Keshav Godge, ...
More related articles
Review On : Orphan Diseases And Treatment...
Shweta P. Manapure, Jayshree R. Khade, Vaibhav P. Uplanchiwar, Vinod M. Thakare, Tamanna B. Barve, ...
A Review On Sustained Release Oral Drug Delivery System...
Sonawane Sudha , Sonali S. Sonawane , Vikas B. Wamane, ...
Review On : Orphan Diseases And Treatment...
Shweta P. Manapure, Jayshree R. Khade, Vaibhav P. Uplanchiwar, Vinod M. Thakare, Tamanna B. Barve, ...
A Review On Sustained Release Oral Drug Delivery System...
Sonawane Sudha , Sonali S. Sonawane , Vikas B. Wamane, ...